Corporate Presentation
October 2019
A LEADING GENE THERAPY BIOTECHNOLOGY COMPANY
GENSIGHT-BIOLOGICS.COM
Disclaimer
This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may
depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward- looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.
2 October 2019 - Non-Confidential
Corporate Overview
Clinical-stage gene therapy company
- Focused on severe retinal degenerative pathologies leading to blindness as well as CNS diseases
- Well positioned to advance disruptive gene therapy technologies in ophthalmology to commercialization
Two disruptive technology platforms
- Mitochondrial targeting sequence (MTS)
- Optogenetics
Lead projects target:
- GS010 - Leber Hereditary Optic Neuropathy (Phase III)
- GS030 - Retinitis pigmentosa and dry-AMD (Phase I/II)
Listed on Euronext Paris (SIGHT)
- Established in 2012, IPO in July 2016 (EUR45m)
- GenSight Biologics Inc incorporated in the US in May 2017
3 October 2019 - Non-Confidential
Executive Team
Bernard Gilly
Chief Executive Officer
PIXIUM VISION (Since 2011) Chairman of the Board, Founder
FOVEA PHARMA (2005-2009)Chairman & CEO - sold to Sanofi
SOFINNOVA PARTNERS (2000-2005)Managing Partner
TRANSGENE (1992-2000) Chairman & CEO
Ph.D. in biology and bio-economics
4 October 2019 - Non-Confidential
Thomas Gidoin
Chief Financial Officer
DBV TECHNOLOGIES (2012-2015)
VP of Finance
IPSEN (2008-2011)
UK Operations Controller (London)
Senior Financial Analyst (Paris)
ERNST & YOUNG (2007-2008)
Auditor
Magali Taiel
Chief Medical Officer
ProQR THERAPEUTICS (2016-2018)VP of Clinical Development
ELI LILLY (2014-2016) Medical Department Lead
PFIZER (2001-2004) Medical Advisor
SERVIER (1999-2001)
R&D International Project Manager MD, Board-certified ophthalmologist
Our target: degenerative retinal diseases with underlying genetic causes
Unmet need: high
LEBER HEREDITARY OPTIC
NEUROPATHY (LHON)
1. Degeneration of RGCs | 1 |
- Inexorable progression to blindness for most patients
- No approved treatments*
Genetic mutations | The eye: an ideal laboratory | |
• | Intravitreal injections to introduce of genetic | |
• | Immune-privileged, closed system | |
Aging | • | material close to target cells |
Slow turnover of retinal cells support long- | ||
term expression of transduced genes |
2. Degeneration of photoreceptors | 2 | AAV: proven vector for gene therapy | ||
RETINITIS PIGMENTOSA (RP) | • | Proven safety and proof of effect in humans | ||
• | Efficient transduction of retinal cells | |||
GEOGRAPHIC ATROPHY | • | No need to screen patients for Nab before | ||
(Late stage form ofAge-Related | • | treatment | ||
Macular Degeneration - AMD) | Validated manufacturing process |
Source: Company | |
5 October 2019 - Non-Confidential | *Except for exceptional circumstances for idebenone in Europe |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Gensight Biologics SA published this content on 16 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2019 14:57:05 UTC